Literature DB >> 10793165

Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.

D D Patel1, M E Gooding, R E Parrott, K M Curtis, B F Haynes, R H Buckley.   

Abstract

BACKGROUND: Immune function can be restored in infants with severe combined immunodeficiency by transplantation of unfractionated bone marrow from HLA-identical donors or T-cell-depleted marrow stem cells from haploidentical donors, with whom there is a single haplotype mismatch, without the need for chemotherapy before transplantation or prophylaxis against graft-versus-host disease. The role of the thymus in this process is unknown.
METHODS: We analyzed the phenotypes of circulating T cells and the proliferative responses of peripheral-blood mononuclear cells to phytohemagglutinin in 83 patients with severe combined immunodeficiency who received allogeneic marrow transplants without T-cell ablation from related donors over an 18-year period. We also tested for the presence of episomes of T-cell antigen receptors (extrachromosomal DNA circles formed during intrathymic T-cell development) to assess thymus-dependent T-cell reconstitution.
RESULTS: Before and early after transplantation, the numbers of circulating T cells were low, with a predominance of mature CD45RO+ T cells (primarily resulting from the transplacental transfer of maternal cells); T-cell antigen-receptor episomes were undetectable in peripheral-blood mononuclear cells. In 73 of the infants, thymus-derived T cells expressing CD45RA and T-cell antigen-receptor episomes were detected within three to six weeks after transplantation. The mean (+/-SD) value for thymus-dependent T-cell antigen-receptor episomes peaked (at 7311+/-8652 per microgram of peripheral-blood mononuclear-cell DNA) 1 to 2 years after transplantation and declined to low levels (less than 100 episomes per microgram of DNA) within 14 years, as compared with a gradual decline from birth to the age of about 80 years in normal subjects.
CONCLUSIONS: The vestigial thymus in infants with severe combined immunodeficiency is functional and can produce enough T cells after bone marrow transplantation to provide normal immune function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793165     DOI: 10.1056/NEJM200005043421804

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  38 in total

Review 1.  Hematopoietic stem cell transplantation for severe combined immune deficiency.

Authors:  K I Weinberg; N Kapoor; A J Shah; G M Crooks; D B Kohn; R Parkman
Journal:  Curr Allergy Asthma Rep       Date:  2001-09       Impact factor: 4.806

Review 2.  Autologous haematopoietic stem cell transplantation in juvenile idiopathic arthritis.

Authors:  L R Wedderburn; M Abinun; P Palmer; H E Foster
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

Review 3.  Reversing T cell immunosenescence: why, who, and how.

Authors:  Pierre Olivier Lang; Sheila Govind; Richard Aspinall
Journal:  Age (Dordr)       Date:  2012-02-26

Review 4.  The long quest for neonatal screening for severe combined immunodeficiency.

Authors:  Rebecca H Buckley
Journal:  J Allergy Clin Immunol       Date:  2012-01-24       Impact factor: 10.793

5.  Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles.

Authors:  Jennifer M Puck
Journal:  J Allergy Clin Immunol       Date:  2012-01-29       Impact factor: 10.793

6.  A new direction for gene therapy: intrathymic T cell-specific lentiviral gene transfer.

Authors:  Ruth Seggewiss; Cynthia E Dunbar
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

7.  First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases.

Authors:  M Louise Markert; José G Marques; Bénédicte Neven; Blythe H Devlin; Elizabeth A McCarthy; Ivan K Chinn; Adriana S Albuquerque; Susana L Silva; Claudio Pignata; Geneviève de Saint Basile; Rui M Victorino; Capucine Picard; Marianne Debre; Nizar Mahlaoui; Alain Fischer; Ana E Sousa
Journal:  Blood       Date:  2010-10-26       Impact factor: 22.113

8.  In vivo correction of ZAP-70 immunodeficiency by intrathymic gene transfer.

Authors:  Oumeya Adjali; Gilles Marodon; Marcos Steinberg; Cédric Mongellaz; Véronique Thomas-Vaslin; Chantal Jacquet; Naomi Taylor; David Klatzmann
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

9.  The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease.

Authors:  Il-Kang Na; Sydney X Lu; Nury L Yim; Gabrielle L Goldberg; Jennifer Tsai; Uttam Rao; Odette M Smith; Christopher G King; David Suh; Daniel Hirschhorn-Cymerman; Lia Palomba; Olaf Penack; Amanda M Holland; Robert R Jenq; Arnab Ghosh; Hien Tran; Taha Merghoub; Chen Liu; Gregory D Sempowski; Melissa Ventevogel; Nicole Beauchemin; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

10.  Matched unrelated bone marrow transplant for Omenn syndrome.

Authors:  Amit Nahum; Brenda Reid; Eyal Grunebaum; Chaim M Roifman
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.